Intrinsa: An Inquiry into Female Sexual Dysfunction and Testosterone
نویسنده
چکیده
In December 2004, the Food & Drug Administration rejected Intrinsa, a testosterone transdermal system for the treatment of hypoactive sexual desire disorder in surgically menopausal women. Intrinsa, as well as the FDA’s decision, sparked considerable controversy. Principally, it raised questions about the use of testosterone to treat sexual dysfunction in women. This paper examines the relationship between testosterone and female sexual dysfunction and explores, specifically, whether there is a causal relationship between depressed testosterone levels and sexual problems in women. It discusses normal female sexual response and female sexual dysfunction as well as the association between testosterone and sexual difficulties in normal and surgically menopausal women. Ultimately, this paper concludes that there is little evidence for a causal relationship between low levels of testosterone and sexual dysfunction in normal women, but that depressed testosterone levels may be associated with sexual problems in surgically menopausal women. Though Intrinsa was purportedly created for use in surgically menopausal women, its off-label use by normal women was probable. Facing this widespread use by women unlikely to be helped by testosterone and subject to its unknown adverse side effects, the FDA appropriately requested more safety data before approving Intrinsa. In December 2004, the Food & Drug Administration rejected Intrinsa, a testosterone transdermal system for the treatment of hypoactive sexual desire disorder in surgically menopausal women. Intrinsa, as well as the FDA’s decision, sparked considerable controversy. Many sexual health researchers argued that Intrinsa was not an appropriate treatment for female sexual dysfunction, but was, instead, the result of the pharmaceutical industry’s efforts to create a disease for financial gain. Others believed that Intrinsa should have been approved and that the FDA’s grounds for rejection were improper. The debate surrounding Intrinsa heightened awareness of women’s sexuality and sexual difficulties. It also raised questions about female
منابع مشابه
P-137: Sex Hormones Abnormalities and Female Sexual Dysfunction in Multiple Sclerosis Patients
Background: Multiple sclerosis (MS) is the most common cause of progressive neurological disability in young adults who may be sexually active. MS patients experience high levels of sexual dysfunction with hypoactive sexual behavior and abnormalities in hypothalamus- pituitary-gonad (HPG) axis. In the present study, we aimed to evaluate the correlation between serum levels of sex hormones durin...
متن کاملAB52. What’s new in treatment of female sexual dysfunction?
For recent a decade, field of female sexual dysfunction for classification, it’s pathophysiology and treatment has been focused. However, the treatment of female sexual dysfunction especially many potential drugs, has been not approved by their government control since their safety or efficacy. Although these present states, many drugs for enhancing sexual desire or genital blood flow have been...
متن کاملPnm-6: Sexual Dysfunction in Women Seeking Fertility Treatment Jahanian Sadatmahalleh
Background: To determine the impact of infertility on all aspects of female sexual function. Materials and Methods: A literature search was conducted on PubMed. Several methods have been used for evaluation of female sexual functions one of them is the questionnaire included of the female sexual function index (FSFI). FSFI is currently the most frequently used female sexual dysfunction question...
متن کاملFemale sexual dysfunction and hormonal status in spinal cord injured (SCI) patients.
To investigate a possible correlation between sexual hormonal status and the presence of female sexual dysfunction (FSD) using the Female Sexual Function Index (FSFI) in females with spinal cord injuries (SCI), we selected 39 SCI fertile-aged women. At visit 1, we assessed the presence of FSD using the FSFI, and all individuals were submitted to a blood hormone evaluation on the third day of th...
متن کاملClinical Assessment of Tribulus terrestris Extract in the Treatment of Female Sexual Dysfunction
This is a qualitative-quantitative study based on hospital records of female patients of reproductive age, presenting sexual dysfunction, and treated with 250 mg Tribulus terrestris extract (1 tablet thrice daily for 90 days). Safety monitoring included vital signs, physical examination, laboratory tests, and occurrence of adverse events. Efficacy analysis included results of the Female Sexual ...
متن کامل